Case Report

**Therapeutic Challenges in Systemic Lupus Erythematosus Patient with Pregnancy, Osteoporosis, and Severe Thrombocytopenia: A Case Report and Review of Literature**

Tantangan Terapi pada Pasien Lupus Eritematosus Sistemik dengan Kehamilan, Osteoporosis, dan Trombositopenia Berat: Sebuah Laporan Kasus dan Tinjauan Literatur

Yosefin Ratnaningtyas, Perdana Aditya R
Department of Internal Medicine Faculty of Medicine Universitas Brawijaya Malang

**ABSTRACT**

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that requires long-term corticosteroid treatment that may lead to osteoporosis characterized by low bone mass and microarchitectural deterioration of the trabecular and cortical skeletal. This study presents a severe case of thrombocytopenia in a 25-year old woman with SLE and osteoporosis who underwent routine therapy and was pregnant for the first time. The complexity of pregnancy and autoimmune conditions create therapeutic challenges that need to be considered in SLE patients with pregnancy, osteoporosis, and severe thrombocytopenia.

**Keywords:** Osteoporosis, pregnancy, systemic lupus erythematosus, thrombocytopenia

**ABSTRAK**

Lupus Eritematosus Sistemik (LES) adalah penyakit autoimun kompleks yang membutuhkan pengobatan kortikosteroid jangka panjang yang dapat menyebabkan osteoporosis ditandai dengan penurunan massa tulang dan perubahan mikroarsitektur trabekuler dan kortikal tulang. Kajian ini melaporkan kasus trombositopenia berat pada wanita berusia 25 tahun dengan LES dan osteoporosis yang menjalani terapi rutin dan mengalami kehamilan pertama. Kompleksitas kehamilan dan kondisi autoimun menimbulkan tantangan terapeutik yang perlu dipertimbangkan pada pasien LES dengan kehamilan, osteoporosis, dan trombositopenia berat.

**Kata Kunci:** Kehamilan, lupus eritematosus sistemik, osteoporosis, trombositopenia

**DOI:** http://dx.doi.org/10.21776/ub.jkb.2021.031.03.6
INTRODUCTION

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that attacks various body systems. The condition is characterized by the formation of pathogenic autoantibodies against nucleic acids and their binding proteins due to intolerance to the body’s components. Thrombocytopenia is one of the primary manifestations of ITP in SLE found in 10.9-17.9% of SLE patients. ITP first-line therapy is high-dose corticosteroids that can increase the risk of osteoporosis in SLE patients. The long-term use of corticosteroids in SLE treatment is a specific risk factor for osteoporosis in SLE. Ten percent of patients who received long-term corticosteroid treatment are diagnosed as osteoporosis. The use of drugs in SLE patients also needs to be considered during conception, pregnancy, lactation, and perioperative periods since in the final trimester of pregnancy calcium mobilization and bone resorption will increase. These changes could cause osteoporosis and fractures in pregnant women (1,2). This study reported a Systemic Lupus Erythematosus patient with Primigravida who experienced Osteoporosis and Severe Thrombocytopenia with a focus on osteoporosis therapy in pregnancy.

CASE REPORT

A 25-year-old woman came to the Rheumatology Outpatient Clinic of Dr. Saiful Anwar Hospital (RSSA) with the chief complaint of gum bleeding for the past one week. Bleeding occurs when brushing teeth stop within minutes. There were no other bleeding complaints. The patient has been diagnosed with Systemic Lupus Erythematosus (SLE) in the past five years with manifestations of a low level of platelets and lymphocytes accompanied by joint pain, hair loss, oral ulcers, with positive ANA test result. The patient routinely underwent periodic examinations and obtained a therapy of chloroquine 1x250 mg, methylprednisolone at reduced doses, calcium lactate 2x500 mg, and mycophenolate sodium 2x180 mg.

The patient was diagnosed with osteoporosis when she was 23 years old through BMD examination and underwent treatment with risedronate 35mg/week for the past 1.5 years. The patient knew her pregnancy three weeks before a visit to the hospital with a gestational age of 12-14 weeks. Since knowing the pregnancy, the patient had been advised to repeat the BMD examination annually for therapy evaluation. Laboratory examination on December 10th, 2019 showed thrombocytopenia (15,000/μL) with a 13% increase in immature platelet fraction (IPF) and Vitamin D 25-OH deficiency at 9.2 ng/ml (<12). The diagnosis determined for the patient was Systemic Lupus Erythematosus with manifestations of severe thrombocytopenia, G1P0A0, 12-14 weeks gestational age, with osteoporosis, and vitamin D deficiency.

Intravenous therapy given was Methylprednisolone 2x62.5 mg for five days and administration of normal fluid saline 1500 cc/24 hours, TC transfusion 1 pack/24 hours to avoid alloimmunization. The oral administrations were folic acid 1x1 mg, CaCO3 2x500 mg, Azathioprine 2x50 mg and cholecalciferol 3x400 iu as adjunctive therapy for osteoporosis. The patient must undergo non-pharmacological therapy, including bed rest on a high-calorie, high-protein diet. The Obstetrics and Gynecology Division monitored antenatal care with conservative care. The patient underwent clinical and laboratory improvement during the treatment (Figure 1), resulted in stable hemodynamics with no signs of re-bleeding during the treatment.

After the treatment at the hospital, patients underwent regular periodic examinations at the Rheumatology clinic. The continued treatment included Methylprednisolone 3x16 mg tapering 4 mg/week, Folic Acid 1x1 mg, CaCO3 2x500 mg, Azathioprine 2x50 mg, and Cholecalciferol 3x400 iu. During outpatient care, laboratory results showed an increase in platelet count and 25-OH vitamin D level (Tabel 1), and there were no complaints of bleeding or pain in the bones. The patient delivered a baby girl on June 29th, 2020 without complications. Birth weight was 2350 g.
gram, physical examination showed no abnormalities.

DISCUSSION
This case report found osteoporosis in early pregnancy with vitamin D deficiency in an SLE patient. This condition could increase the risk of pathological fracture in the patient because the last six weeks of pregnancy. The mother will lose 300-500 mg of calcium per day for the fetal osteogenesis, and approximately 200 mg of calcium is lost each day through breastfeeding, thus affecting calcium metabolism of the mother. During pregnancy and after childbirth, intestinal calcium absorption increases to meet the calcium levels needed in the breast milk. Increased maternal bone resorption can cause fractures in the mother.

Some of the therapeutic approaches chosen in this case were to stop administering risedronate and followed by supplementation of vitamin D and calcium. Various studies have presented therapeutic options for osteoporosis in pregnancy, including bisphosphonates (3). A study by Levy et al., in 21 pregnant women exposed to various types of bisphosphonates, that were alendronate (n=12), etidronate (n=5), risendronate (n=2), and pamidronate (n=2), found no abnormalities in neonates compared to the control group (4). These data were validated by a systematic review of 51 cases of exposure to various types of bisphosphonates before or during pregnancy that did not find cases of bone abnormalities or other congenital abnormalities in neonates. Djojanovic et al., reported in a case series of 24 pregnancies with pre-pregnancy or early pregnancy exposure to alendronate, and there were 19 live birth infants and five miscarriages. No major congenital anomalies were found (5).

However, the administration of bisphosphonates must be avoided in pregnancy because this drug can pass through the placenta and last long in the bones, so there is a potential risk of exposure to the fetus, especially in unplanned pregnancies. Two major concerns need to be considered regarding bisphosphonate therapy in pregnant women. First, bisphosphonates are category C drugs for fetal safety because data on a mouse model show toxic effects due to the accumulation of bisphosphonates in the fetal skeleton, although many case reports in humans show no adverse effects on the mother or fetus. Secondly, although bisphosphonate therapy in pregnant patients with osteoporosis in the short term can show an improved picture of BMD, the effectiveness in preventing fractures and the long-term risk of bisphosphonate exposure remains unclear (3,6).

There are several studies on osteoporosis treatment in post-partum patients (Appendix 1). Sairkaya et al. (2004) established a significant improvement in BMD measurements of patients treated with Alendronate–Na 10 mg/day and calcium carbonate 1000 mg/day for six months (7). Research by Allalli et al., Grizzo et al., and Zhang et al., identified a significant increase in BMD of patients given vitamin D and calcium supplementation (8-10). Teriparatide, a recombinant human parathyroid hormone 1–34, has been considered a potential therapeutic agent for osteoporosis. Polat et al., and Ijuin et al., reported a significant increase in BMD of patients treated with cholecalciferol, calcium, and teriparatide (11,12). Winarno et al., presented a successful treatment of 1–34 parathyroid hormone (PTH) after the failure of bisphosphonate therapy in cases of pregnancy-associated osteoporosis and complex multiple fractures. After 18 months of treatment of PTH1–34, the BMD of the patients improved (13). Despite this, no data are available regarding the risk of congenital disorders, miscarriage, or adverse outcomes in the mother or fetus due to the use of teriparatide in pregnant women. Consideration of discontinuing the drug when pregnancy is known has been suggested even though the use of teriparatide can be used for patients with recurrent fractures or high-risk fractures (5).

Selective estrogen receptor modulators (SERMs) are a group of estrogen receptor agonist/antagonist with tissue-selective effects.Raloxifene, lasofoxifene, and basedoxifene have been approved as a treatment for osteoporosis in Europe. Raloxifene is the only SERM currently approved by the US FDA for the prevention and treatment of osteoporosis. Raloxifene significantly decreases bone resorption and turnover, increases BMD 2–3% in the hip and spine, and decreases vertebral fracture incidence by 30–50%. However, the effect of the drug on pregnancy has not been established by the US FDA. This drug is classified as AU TGA pregnancy category X that means this drug has a high risk of causing permanent damage to the fetus and should not be used in pregnancy or when there is a possibility of pregnancy. Based on the action mechanism, this drug could block the important functions of estrogen at all stages of pregnancy (14). Romosozumab, a specific inhibitor of sclerostin, is also a new and unique approach to the treatment of postmenopausal osteoporosis and related disorders. The decreased relative risk of vertebral fracture during the

<table>
<thead>
<tr>
<th>Laboratorium findings</th>
<th>1st visit</th>
<th>2nd visit</th>
<th>3rd visit</th>
<th>4th visit</th>
<th>5th visit</th>
<th>6th visit</th>
<th>7th visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (g/dl)</td>
<td>10.8</td>
<td>11.1</td>
<td>10.4</td>
<td>9.9</td>
<td>9.3</td>
<td>10.7</td>
<td>10</td>
</tr>
<tr>
<td>Platelet (x10^3/μL)</td>
<td>35.00</td>
<td>32.00</td>
<td>38.00</td>
<td>41.00</td>
<td>50.00</td>
<td>62.00</td>
<td>79.00</td>
</tr>
<tr>
<td>PT/PTT (sec)</td>
<td>11.4/31.9</td>
<td>9.8/26.5</td>
<td>8/25.1</td>
<td>8.3/24.6</td>
<td>8.2/25.1</td>
<td>8.0/24.6</td>
<td>8.5/25.1</td>
</tr>
<tr>
<td>INR</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPF (%)</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D 25-OH (ng/mL)</td>
<td>9.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgM Anti Cardiolipin MPL(U/mL)</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG Anti Cardiolipin MPL(U/mL)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Subsequent Laboratorium Findings demonstrated improvement in platelet values and vitamin D
second year of therapy in the FRAME study showed an 80% greater reduction in vertebral fracture risk in patients receiving romosozumab followed by denosumab when compared with the placebo group. In the ARCH study, the effects of romosozumab were superior to alendronate therapy that showed a 48% greater reduction in spinal fractures during the 2nd year of therapy. In the clinical trials, romosozumab has been well-tolerated, but romosozumab is not indicated for use in women who have the potential for pregnancy. In animal studies, weekly administration of romosozumab to pregnant rats during the period of organogenesis showed 32 times greater exposures and resulted in fetal bone abnormalities (15,16).

Pregnancy poses a challenge to the mother’s bones because the construction of the fetal skeleton requires substantial calcium transfer. This process is very intense during the third trimester when fetal bones undergo substantial growth and calcification; the mother bears this mechanism, which can produce a degree of damage to the mother’s bones unless there is a sufficient compensation mechanism from the mother. If an adequate balance is not achieved, pregnancy will increase susceptibility to the mother’s bones. Inadequate adjustment in the mother will cause more decalcification in the skeleton of the mother’s bones, especially in the third trimester, when calcium transfer increases dramatically. Therefore, the concentration of vitamin D must be increased during pregnancy. Changes in vitamin D, together with increased efficiency of intestinal calcium absorption, doubles its capacity to help mothers accommodate the fetus’s need for calcium (17,18).

The patient in this case report was given 2x500 mg of calcium supplementation and 3x400 mg of vitamin D cholecalciferol. The choice of therapy was based on consistent evidence from RCT studies, and a meta-analysis that vitamin D supplementation combined with calcium reduces the risk of falls and fractures. Active vitamin D is not preferred because of an increased risk of hypercalcemia. Additional calcium supplements can be considered if the daily calcium intake is below 700 mg/day, with a maximum daily supplement dose of 1000 to 1200 mg. For calcium supplementation combined with vitamin D, the recommended minimum dose of vitamin D is 800 IU (16,19,20).

Bergman et al., also support the use of cholecalciferol 800 IU/day to reduce the incidence of non-vertebral and hip osteoporotic fractures. In the study, cholecalciferol with calcium provided better benefits compared to calcium alone. Vitamin D supplementation was given to achieve or maintain the 25 (OH) D level of at least 50 nmol/L with a better target >75 nmol/L in all patients. A systematic review by Cochrane, the safety of vitamin D supplementation, or in combination with calcium or other vitamins and minerals in pregnant women shows that there are no studies reporting eclampsia, and only one study (n=400 women) reports pre-eclampsia in mothers. Pregnant women who receive vitamin D supplementation are less likely to have babies with a birth weight below 2500 g compared to women who do not receive the treatment (20).

The Royal College of Obstetricians and Gynecologists (RCOG) also recommends for high-risk women (women who have increased skin pigmentation, reduced sun exposure, and obesity) to get vitamin D supplementation of at least 800 units/day that can be combined with calcium. A study showed that dosages of cholecalciferol up to 4,000 iu per day are safe in pregnant women and are effective even though high doses of vitamin D (300,000-500,000 iu) is not recommended in pregnancy (17).

In this case, the patient also experienced thrombocytopenia with clinical symptoms of gum bleeding. Thrombocytopenia puts the mother and fetus at a greater risk of bleeding, especially if the platelet levels are less than 20,000/μL (18,21). Thrombocytopenia, as one of the primary manifestations of ITP in SLE, is found in 10.9-17.9% of SLE patients with high-dose corticosteroids as the first-line therapy. In this disorder, antiplatelet autoantibodies are found in 60% of SLE patients who are mostly IgG (60%). Antigens from antiplatelet antibodies include glycoprotein Ia/IIa (GpIa/IIa), glycoprotein lib/Illa (Gplib/Illa), glycoprotein membrane (allaβ3integrin), and glycoprotein lib/Illa. Other causes of autoimmune-mediated thrombocytopenia are antiphospholipid antibodies, antibodies to thrombopoietin and its receptors, and genetics (2). The specific therapy for SLE immune thrombocytopenia is similar to Primary ITP. In pregnancy, steroids or IVIG are recommended before 36 weeks of pregnancy if the platelet count is under 30,000/μL, the patient is symptomatic, or an invasive procedure is considered. When approaching the delivery, the goal of therapy is to maintain platelet counts above 50,000/μL. Prednisone 1 mg/kgBW could be used for treatment during pregnancy with a visible therapeutic response within 2-14 days, and Azathioprine can be given in pregnancy at a dose of 1.5-2 mg/kg/day (maximum 150 mg/day). IVIG can be considered when first-line therapy fails, or there is life-threatening bleeding, and ongoing infection occurs. Intravenous immunoglobulin at a dose of 1 g/kg has a relatively fast therapeutic response (within 1-3 days). IVIG can be given without corticosteroids (22).

The most common maternal complications of thrombocytopenia in pregnancy are bleeding, such as antepartum hemorrhage, intrapartum hemorrhage, and post-partum hemorrhage whereas complications in neonates depend on the underlying disease. In patient management, the patient was given a TC transfusion 1 pack/day in order to reduce the risk of bleeding and avoid the formation of anti-platelet antibodies that often occurred if the patient was frequently given transfusions. IgG anti thrombocyte antibodies circulate in the blood circulation and have the ability to cross the placental blood barrier that could cause thrombocytopenia in the fetus that manifests purpura, ecchymosis, meleena, or intracranial hemorrhage in the neonatal period (21).

Considering the risk of alloimmunization in patients receiving repeated platelet transfusions, it is important to know the transfusion response and the relationship of antibodies formed to the given platelet transfusion response. A study by Lubis et al., at RSCM showed that there was a relationship between HLA antibody class 1 with platelet transfusion response. Patients with positive class 1 HLA antibodies were a risk of experiencing 11.4 times of transfusion failure (Adjusted PR 11.4; 95% CI 2.19-58.557; p=0.004) (23). Data from previous studies indicate that there are 24-44% of TC transfusion failures in achieving satisfactory responses. This can be caused by non-immunological factors (63-67%) that cause a decrease in platelet survival, such as sepsis, hepatosplenomegaly, massive bleeding, disseminated intravascular coagulation,
or administration of certain drugs. Other causes are immunological factors (18-25%) that cause platelet destruction from transfusion through antibody mediation due to alloimmunization of HLA, antigens in white blood cells and platelets, or both. The incidence of alloimmunization is higher in patients with a history of pregnancy than in the group without a history of pregnancy or transfusion. Antibodies against HLA class 1 were detected as much as 30% in a history of three times of pregnancy or more. This can be due to the existence of memory cells that can be activated by cells or cell fragments with HLA class 1.

The transfusion process stimulates the mother’s immune system during pregnancy. This might explain the tendency for higher HLA antibodies in patients with a history of pregnancy. Antibodies to platelet specific antigens (human platelet antigens/HPA) have not been detected much, but it is known that 10% of women with HPA-1b are immunized with HPA-1a antigens during pregnancy. Based on several prospective studies, alloimmunization occurs on more than three times transfusions, whereas in other studies, it occurs on transfusions that are more than seven times. A study by Lubis et al., showed only 3 out of 36 (8.3%) transfusions using leukocyte depleted platelet concentrates, most of the transfusion used concentrated platelets (non-leukocyte depleted). The use of leukocyte depleted transfusions reduces the incidence of HLA alloimmunization. This is due to decreased antigen presentation by donor leukocytes and reduced amount of HLA class 1 antigens. Data showed that about 50% of patients with a history of pregnancy, who are transfused with non-leukocyte depleted, formed antibodies against HLA. The TRAP study shows the benefits of using leukocyte depleted transfusion in patients with a history of pregnancy. Reducing donor exposure by using single donor apheresis is considered to slow the incidence of alloimmunization (23).

There is no official guideline in the treatment of pregnancy with osteoporosis. The treatment options are limited to reported cases. The termination of breastfeeding is recommended in most cases. Other options include calcium and vitamin D supplementation with a recommended daily calcium dose of 1000 to 1200 mg, and the recommended vitamin D is cholecalciferol with a minimum dose of 800 IU/day. Bisphosphonates and teriparatide can be given to treat post-partum vertebral fractures. Azathioprine with a minimum dose of <1.5-2 mg/kg/day can be given to SLE patients with ITP who are pregnant. The higher risk of platelet alloimmunization in pregnancy indicates the need for caution of platelet transfusion in pregnancy or the use of apheresis or leukocyte depleted platelet transfusion in patients with pregnancy to avoid the risk of alloimmunization.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest.

**REFERENCES**


138.


